Rise Health & Wellness Peptides

Retatrutide is a triple receptor agonist targeting GLP-1, GIP, and glucagon receptors:

1. GLP-1 Receptor Agonism: Stimulates insulin secretion in response to nutrient intake, reduces glucagon release, and delays gastric emptying to enhance satiety.

2. GIP Receptor Agonism: Enhances insulin sensitivity and works synergistically with GLP-1 pathways to regulate glucose metabolism and lipid handling.

3. Glucagon Receptor Agonism: Increases energy expenditure, promotes lipolysis, and contributes to enhanced fat oxidation.

1. Substantial Weight Reduction – Phase 2 Trial

• Study focus: 48-week randomized clinical trial in individuals with obesity
• Key findings: Up to 24.2% reduction in body weight
• Published in: New England Journal of Medicine (2023)

2. Enhanced Glycemic Control

• Study focus: Effects in participants with type 2 diabetes
• Key findings: Significant reductions in HbA1c and improved glycemic markers
• Published in: The Lancet

3. Improvement in Liver Health

• Study focus: Hepatic fat content analysis
• Key findings: Up to 82% relative reduction in liver fat in Phase 2 study participants
• Published in: Nature

4. Cardiometabolic Benefits

• Study focus: Lipid and cardiovascular biomarkers
• Key findings: Up to 40.6% triglyceride reduction and significant apoC-III decreases
• Reported by: Reuters (clinical trial coverage)